Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Taladegib |
Synonyms | |
Therapy Description |
Taladegib inhibits the Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (PMID: 22007748, Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1: Abstract #2819). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Taladegib | LY2940680|LY-2940680 | SMO Inhibitor 16 | Taladegib (LY-2940680) inhibits the Smo, thereby inhibiting Hedgehog signaling and subsequent cell proliferation (PMID: 22007748, Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1: Abstract #2819, PMID: 29483143, PMID: 29453627). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMO wild-type | medulloblastoma | sensitive | Taladegib | Preclinical | Actionable | In a preclinical study, LY2940680 was demonstrated to bind to the Smo receptor and inhibit hedgehog signaling in a human medulloblastoma tumor cell line (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819). | detail... |
SMO T241M | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
SMO W281C | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
SMO V321M | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
SMO A459V | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
SMO I408V | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
SMO D473H | Advanced Solid Tumor | sensitive | Taladegib | Preclinical | Actionable | In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819). | detail... |
SMO C469Y | Advanced Solid Tumor | decreased response | Taladegib | Preclinical | Actionable | In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). | 25759019 |
Unknown unknown | basal cell carcinoma | not applicable | Taladegib | Phase I | Actionable | In a Phase I trial, Taladegib treatment resulted in a clinical response in 46.8% (22/47) of patients with basal cell carcinoma, including 16 patients with a confirmed partial response, 1 patient with an unconfirmed partial response, and 5 patients with a confirmed complete response (PMID: 29483143). | 29483143 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02530437 | Phase Ib/II | Taladegib Carboplatin + Paclitaxel | A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | Active, not recruiting | USA | 0 |
NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | 1 |